ELFABRIO (Chiesi Australia Pty Ltd)
Product name
ELFABRIO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
174 (255 working days)
Active ingredients
pegunigalsidase alfa
Registration type
NCE/ NBE
Indication
ELFABRIO is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.